Immune responses in the convalescence stage of COVID-19 patients

Immune responses in the convalescence stage of COVID-19 patients - Immune responses in the convalescence stage of COVID-19 patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041227

Enrollment

700

Registered

2020-07-28

Start date

2020-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 (SARS-CoV-2 infection)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who meet all of the following criteria are eligible. (1) Patients who are 20 years of age or older at the time of registration. (2) Patients residing in Japan. (3) Patients with positive results on the PCR, Lamp, or antigen testing of pharyngeal swab, nasopharyngeal swab, or saliva. (4) Patients with previous COVID-19 infection confirmed by physicians. (5) Patients who have provided consent to inquire about information on diagnosis and treatment of COVID-19 from the medical institution or health center where the diagnosis or treatment of COVID-19 was performed. (6) Patients who have given their written informed consent to participate in this study.

Exclusion criteria

Exclusion criteria: Patients who meet the following criteria are excluded. (1) Patients with mental illness or other conditions that might affect their ability to consent (2) Patients with a fever of 37 degrees or more, cough or breathlessness, sore throat, abnormalities in taste or smell, intensive contact with COVID-19 patients, or a history of foreign travel within 2 weeks of the scheduled blood collection date. (3) Patients who are deemed by the researcher to be unsuitable to participate in the research.

Design outcomes

Primary

Measure	Time frame
Correlation between the neutralizing activity and the NP antibody titers at 26 (20 - 32) and 52 (46 - 58) weeks after the date of the first positive PCR or other test for COVID-19 infection	—

Secondary

Measure	Time frame
(1) Distribution of NP antibodies (quantitative and qualitative), SP antibodies (quantitative), and neutralizing activity at 26 (20 - 32) and 52 (46 - 58) weeks after the first positive PCR or other test for COVID-19 infection by sex and age group. (2) Correlation between neutralizing activity and NP antibody titer by presence of symptoms (3) Correlation between neutralizing activity and NP antibody titer by severity of illness (severe cases requiring tracheal intubation or ECMO) (4) Correlation between neutralizing activity and SP antibody titers at 26 (20 - 32) and 52 (46 - 58) weeks after the first positive test for COVID-19 infection, including PCR (5) Association of baseline background factors, hospitalization status, treatment status, and severity of disease with neutralizing activity values at 26 (20 - 32) and 52 (46 - 58) weeks after the first positive PCR or other test. (6) Association of baseline background factors, treatment status, and severity of disease with NP antibody titers at 26 (20 - 32) and 52 (46 - 58) weeks after the first positive PCR or other test for COVID-19 infection.	—

Measure

Time frame

(1) Distribution of NP antibodies (quantitative and qualitative), SP antibodies (quantitative), and neutralizing activity at 26 (20 - 32) and 52 (46 - 58) weeks after the first positive PCR or other test for COVID-19 infection by sex and age group. (2) Correlation between neutralizing activity and NP antibody titer by presence of symptoms (3) Correlation between neutralizing activity and NP antibody titer by severity of illness (severe cases requiring tracheal intubation or ECMO) (4) Correlation between neutralizing activity and SP antibody titers at 26 (20 - 32) and 52 (46 - 58) weeks after the first positive test for COVID-19 infection, including PCR (5) Association of baseline background factors, hospitalization status, treatment status, and severity of disease with neutralizing activity values at 26 (20 - 32) and 52 (46 - 58) weeks after the first positive PCR or other test. (6) Association of baseline background factors, treatment status, and severity of disease with NP antibody titers at 26 (20 - 32) and 52 (46 - 58) weeks after the first positive PCR or other test for COVID-19 infection.

—

Countries

Japan

Contacts

Public ContactAtsushi Goto

Yokohama City University, Graduate School of Data Science Department of Health Data Science

agoto@yokohama-ac.jp045-787-2215

Outcome results